Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Medstar Health Research Institute
Study ID
NCT00006669
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • sargramostim — BIOLOGICAL
  • EPOCH regimen — DRUG
  • cyclophosphamide — DRUG
  • doxorubicin hydrochloride — DRUG
  • etoposide — DRUG
  • prednisone — DRUG
  • vincristine sulfate — DRUG

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to kill cancer cells. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab followed by combination chemotherapy in treating patients who have refractory or recurrent non-Hodgkin's lymphoma.

Key Dates

Start date
Sep 30, 1999
Status verified
May 2001
Primary completion
Jan 31, 2000
Completion
Jan 31, 2000

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Washington Cancer InstituteWashington D.C.District of Columbia20010-
Franklin Square Hospital CenterBaltimoreMaryland21237-

Find similar trials in Washington D.C., DC

By research site
Washington Cancer Institute· Washington D.C., DCFranklin Square Hospital Center· Baltimore, MD

Related Studies